Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
No.                                     Description

  10.1       Option Agreement, dated January 23, 2023, by and among Iovance
           Biotherapeutics, Inc., Iovance Biotherapeutics UK Ltd, Clinigen
           Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc.*
104        Cover Page Interactive Data File (embedded within the Inline XBRL
           document).

* Schedules and exhibits omitted pursuant to Item 601(b)(10) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.

© Edgar Online, source Glimpses